List of Excipients in Branded Drug SESQUIENT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sedor Pharmaceuticals LLC	SESQUIENT	fosphenytoin sodium	80674-102	BETADEX SULFOBUTYL ETHER SODIUM
Sedor Pharmaceuticals LLC	SESQUIENT	fosphenytoin sodium	80674-102	HYDROCHLORIC ACID
Sedor Pharmaceuticals LLC	SESQUIENT	fosphenytoin sodium	80674-102	SODIUM HYDROXIDE
Sedor Pharmaceuticals LLC	SESQUIENT	fosphenytoin sodium	80674-102	TROMETHAMINE
Sedor Pharmaceuticals LLC	SESQUIENT	fosphenytoin sodium	80674-102	WATER

SESQUIENT Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

SESQUIENT is an injectable fosphenytoin sodium product for intravenous or intramuscular administration. Its core commercial value is operational rather than excipient-driven: fosphenytoin provides a water-soluble prodrug of phenytoin, while the formulation uses a limited excipient system designed for parenteral compatibility. The strongest opportunities are ready-to-administer presentations, hospital workflow improvements, supply assurance, and differentiated container-closure systems rather than aggressive excipient substitution.

What is SESQUIENT and how is it formulated?

SESQUIENT contains fosphenytoin sodium, expressed as phenytoin sodium equivalents, for the management of generalized tonic-clonic status epilepticus and prevention or treatment of seizures during neurosurgery. The product is administered intravenously or intramuscularly and is supplied as a concentrated solution in single-dose vials.[1]

Attribute	SESQUIENT profile
Active ingredient	Fosphenytoin sodium
Therapeutic class	Antiseizure agent; hydantoin prodrug
Administration	Intravenous or intramuscular
Strength	100 mg phenytoin sodium equivalents per mL
Dosage form	Sterile injectable solution
Commercial container	Single-dose vial presentation
Primary clinical use	Status epilepticus and perioperative seizure management
Key formulation issue	Maintaining solution stability, compatibility, and safe rapid administration
Regulatory pathway	FDA-approved prescription drug product; product-specific FDA labeling applies

Fosphenytoin is converted to phenytoin after administration. Compared with injectable phenytoin, the prodrug has improved aqueous solubility and avoids some formulation limitations associated with phenytoin sodium injection, including the use of organic cosolvents and strong alkalinity.[1,2]

What excipients are used in SESQUIENT?

The principal inactive ingredients identified in the FDA prescribing information are tromethamine, hydrochloric acid, and water for injection.[1]

Excipient	Likely formulation function	Commercial relevance
Tromethamine	Buffering and pH control	Supports solution stability and product performance
Hydrochloric acid	pH adjustment	Enables final pH control during manufacture
Water for injection	Vehicle	Provides the parenteral solvent system

The formulation is intentionally narrow. A small excipient system reduces the number of variables affecting toxicology, extractables and leachables, sterilization, compatibility, and regulatory review. It also limits opportunities to create meaningful composition-of-matter differentiation through conventional excipient replacement.

Tromethamine is the principal strategic excipient. Its value is not a new therapeutic effect but control of the aqueous environment in which fosphenytoin remains soluble and stable. Hydrochloric acid is primarily a manufacturing and pH-adjustment reagent. Water for injection is the parenteral vehicle and is not a realistic exclusivity lever.

The formulation’s commercial defensibility therefore depends on process control, stability data, container compatibility, and presentation design rather than on a new excipient combination.

What excipient strategy is most commercially viable for SESQUIENT?

The highest-value strategy is formulation preservation combined with presentation innovation. Substituting the buffer system may create technical and regulatory risk without delivering a clear purchasing benefit.

Maintain the established buffer system

A tromethamine-based system has several advantages:

• It is familiar in parenteral development.
• It supports pH adjustment without adding a complex excipient burden.
• It avoids surfactants, preservatives, and organic solvents that can increase tolerability and compatibility concerns.
• It simplifies analytical control and manufacturing transfer.

Any replacement with phosphate, citrate, acetate, histidine, or another buffer would require a new assessment of pH drift, degradation, precipitation, osmolality, injection-site tolerability, compatibility with infusion fluids, and container-closure interaction.

A buffer substitution could be commercially useful only if it produces a measurable advantage, such as longer shelf life, reduced particulate formation, improved dilution compatibility, or a lower-cost manufacturing process. Without one of those outcomes, the change would increase development risk without improving market access.

Avoid unnecessary preservatives

SESQUIENT is a single-dose injectable product. A preservative-free design is commercially attractive in emergency medicine because it reduces concerns about preservative exposure, compatibility, and use in vulnerable patient populations.

Adding benzyl alcohol, phenol, parabens, or other preservatives would create limited value and could weaken the product proposition. Preservatives would also require additional safety, compatibility, and labeling analysis.

Optimize pH and osmolality within the approved product profile

pH is central to fosphenytoin formulation performance. The product must remain soluble during storage, withdrawal, administration, and dilution. A development program should evaluate:

• pH drift over shelf life;
• precipitation after dilution;
• particulate formation;
• compatibility with common infusion solutions;
• adsorption to tubing and syringes;
• stability after vial puncture;
• temperature excursions during hospital handling.

The best commercial outcome is not necessarily the lowest or highest pH. It is a controlled formulation range that provides reliable performance while remaining acceptable for intravenous and intramuscular administration.

What formulation patents could protect SESQUIENT or a competing product?

Potential formulation claims could cover the composition, concentration, pH range, buffer ratio, stability profile, dilution conditions, container closure, or administration method. The practical strength of these claims would vary substantially.

Claim category	Potential value	Main weakness
Fosphenytoin plus tromethamine composition	Moderate	May be vulnerable if the excipient combination is obvious or already disclosed
Defined pH range	Low to moderate	Narrow ranges may be designed around
Long-term stability at a specified temperature	Moderate	Requires strong comparative data and reproducible results
Ready-to-use diluted solution	High commercial value	Manufacturing, sterility, and stability burden is substantial
Prefilled syringe formulation	Moderate to high	Device and container claims may provide stronger differentiation
Low-particulate formulation	Moderate	Requires robust analytical and clinical relevance
Compatibility with infusion systems	Moderate	Can support labeling and hospital adoption, but may be difficult to enforce
Manufacturing process	Moderate	Trade-secret protection may be more practical than patent enforcement

A formulation patent is strongest when the excipient system produces an unexpected technical result. Examples could include materially improved stability, a lower precipitation rate, improved syringeability, or compatibility with a clinically important diluent that is not available with conventional formulations.

A basic claim covering fosphenytoin, tromethamine, hydrochloric acid, and water would face greater validity and freedom-to-operate pressure if similar compositions were already disclosed in fosphenytoin patents, regulatory filings, or prior-art formulations.

What is the Orange Book status and exclusivity timeline for SESQUIENT?

SESQUIENT is an FDA-approved drug product associated with an NDA for fosphenytoin sodium injection. Public FDA product information identifies the product as an approved prescription injectable.[1]

Regulatory issue	Assessment
FDA approval	Approved injectable fosphenytoin product
Approval pathway	Product-specific NDA record; FDA regulatory classification should be confirmed in the current Drugs@FDA record
Orange Book patents	No clearly identified patent-based barrier should be assumed without reviewing the current Orange Book entry
Regulatory exclusivity	Any applicable NDA exclusivity depends on the approval pathway and FDA-recognized exclusivity period
Generic pathway	A competing product may pursue an ANDA or, depending on the reference-product record and differences in formulation or labeling, a 505(b)(2) pathway
Biosimilar pathway	Not applicable; SESQUIENT is a small-molecule drug, not a biologic

The key commercial point is that SESQUIENT does not receive biologic-style reference-product exclusivity. Competitors are not required to develop biosimilars. They may pursue generic or hybrid approval routes, subject to pharmaceutical equivalence, bioequivalence, labeling, manufacturing, and regulatory requirements.

For injectable products, the absence of a visible patent barrier can accelerate competition. However, approval risk can remain significant because sterile manufacturing, container closure, particulate control, extractables and leachables, and injectable product quality requirements are demanding.

When could generic or competing fosphenytoin products enter?

Entry risk depends on four factors:

1. Whether the product has active Orange Book-listed patents.
2. Whether FDA grants or recognizes unexpired regulatory exclusivity.
3. Whether a competitor can demonstrate pharmaceutical equivalence and bioequivalence.
4. Whether the competitor can obtain reliable sterile manufacturing capacity.

A generic fosphenytoin injection could be commercially attractive because the active ingredient is established and the dosage form is relatively simple compared with complex biologics. The manufacturing barrier is still meaningful. Fosphenytoin products require control of:

• Sterility assurance;
• assay and degradation products;
• pH;
• particulate matter;
• extractables and leachables;
• vial closure integrity;
• solution clarity;
• concentration expressed in phenytoin equivalents;
• administration-rate labeling.

A Paragraph IV challenge would be relevant only if a competitor seeks approval before expiration of an Orange Book-listed patent. If no patent is listed, competition could proceed through ordinary abbreviated approval mechanisms, subject to regulatory exclusivity and FDA review.

The most plausible entry scenario is not necessarily a direct vial-for-vial generic. Competitors may target a differentiated presentation, such as a ready-to-use syringe or pharmacy bulk package, if the reference product does not adequately address emergency department, operating room, or intensive-care workflow.

What commercial opportunities exist in SESQUIENT excipient and presentation development?

Ready-to-administer formats

A ready-to-administer formulation could reduce pharmacy preparation time and medication-error risk. Potential formats include:

• Prefilled syringes;
• Ready-to-use infusion bags;
• Unit-dose cartridges;
• Diluted hospital-use presentations;
• Pharmacy bulk packages where permitted by FDA requirements.

The main development challenge is maintaining stability after dilution and throughout the product’s labeled storage period. The product must also remain compatible with the syringe barrel, stopper, needle, tubing, and infusion bag.

Device-linked differentiation

A prefilled syringe could create stronger commercial differentiation than a modest excipient change. Relevant development issues include:

• Dose accuracy;
• delivery volume;
• plunger force;
• siliconization;
• adsorption;
• needle compatibility;
• end-of-use residual volume;
• container-closure integrity;
• emergency-use labeling.

Device patents, container patents, and process know-how may be more defensible than a narrow buffer-composition claim.

Hospital supply and procurement contracts

Fosphenytoin is used in acute-care settings where product availability can influence purchasing decisions. Commercial value can come from:

• dual IV and IM administration;
• consistent supply;
• multiple vial sizes;
• barcode-ready packaging;
• reduced preparation steps;
• predictable dilution instructions;
• lower waste from unit-dose packaging.

The excipient system supports these opportunities by enabling a concentrated aqueous injectable that can be packaged in a compact format. The commercial proposition should focus on workflow and supply reliability rather than claiming a clinical advantage that is not established in comparative trials.

Manufacturing and contract development

A manufacturer with sterile fill-finish capacity can create value through:

• improved aseptic processing;
• higher-yield vial filling;
• reduced line loss;
• automated visual inspection;
• validated cold-chain or room-temperature handling;
• qualified alternate suppliers for tromethamine and container components.

Supply-chain resilience is important because a narrow formulation can create single-source dependency for key raw materials or packaging components. A dual-supplier strategy for tromethamine, vial glass, stoppers, and seals can reduce disruption risk.

How strong is the SESQUIENT patent estate?

The formulation patent estate appears structurally less defensible than estates built around novel active ingredients, long-acting delivery systems, or complex biologics. The likely protection hierarchy is:

1. Regulatory exclusivity, if applicable.
2. Any Orange Book-listed composition or formulation patents.
3. Presentation and device patents.
4. Manufacturing-process patents.
5. Trade secrets involving sterile processing and stability control.

A patent claim directed only to the presence of tromethamine and pH adjustment may have limited blocking power. A claim tied to a defined concentration, stability result, container system, and administration profile could be stronger, particularly if supported by comparative evidence.

The greatest practical barrier may be manufacturing execution. A competitor may be able to design around a formulation claim but still face substantial investment in sterile production, analytical validation, stability studies, and regulatory filing.

How does SESQUIENT compare with injectable phenytoin?

Factor	SESQUIENT	Injectable phenytoin sodium
Active molecule	Fosphenytoin prodrug	Phenytoin sodium
Water solubility	Higher as formulated prodrug	More formulation-limited
Organic cosolvent burden	Lower formulation burden	Historically associated with propylene glycol and alcohol systems
Administration	IV and IM	Primarily IV use in acute settings
Formulation complexity	Aqueous buffered solution	Strongly alkaline solution with greater compatibility concerns
Excipient opportunity	Limited but suitable for presentation innovation	Greater opportunity to reduce formulation liabilities
Competitive positioning	Emergency-use workflow and tolerability profile	Established, lower-cost legacy therapy
Patent strategy	Presentation, stability, and process claims	Reformulation, delivery, and container claims

The competitive threat is not limited to generic fosphenytoin. Hospitals may compare SESQUIENT with phenytoin sodium, levetiracetam injection, valproate sodium injection, and other acute antiseizure therapies. Clinical protocols, formulary status, acquisition cost, administration requirements, and availability affect substitution.

What litigation and settlement issues affect SESQUIENT?

No specific patent litigation or settlement should be assumed without a current review of federal court dockets, FDA Orange Book records, and ANDA litigation filings. The relevant litigation risks would include:

• Paragraph IV challenges to listed patents;
• disputes over formulation or dosage-form claims;
• trademark disputes involving the SESQUIENT brand;
• ANDA applicant litigation under the Hatch-Waxman framework;
• manufacturing patent disputes;
• device or prefilled-syringe infringement claims.

A settlement agreement could delay generic launch even where a patent challenge exists. Its commercial effect would depend on the agreed entry date, authorized-generic rights, manufacturing restrictions, and treatment of alternative presentations.

What should a commercial excipient strategy prioritize?

The preferred strategy is a three-layer program:

1. Preserve the simple aqueous formulation unless a replacement produces a clear stability or administration benefit.
2. Develop differentiated presentations that reduce hospital preparation and dosing friction.
3. Protect the product through device, container, process, and stability claims supported by comparative data.

The most attractive development targets are a prefilled syringe and a stable ready-to-use diluted presentation. Both can command greater commercial value than a minor buffer modification, provided the product remains stable, easy to administer, and compatible with hospital practice.

Key Takeaways

• SESQUIENT is an aqueous fosphenytoin sodium injection using tromethamine, hydrochloric acid, and water for injection.
• The excipient system is narrow and functionally driven, leaving limited room for conventional composition-based differentiation.
• Tromethamine and pH control are central to solution stability and should not be changed without a clear technical benefit.
• Preservative-free positioning is commercially useful for a single-dose emergency injectable.
• The strongest opportunities are prefilled syringes, ready-to-use diluted products, unit-dose formats, and supply-chain differentiation.
• SESQUIENT is a small-molecule product, so biosimilar competition is not relevant.
• Generic entry risk depends on FDA exclusivity, current Orange Book listings, regulatory pathway, and sterile manufacturing capability.
• Device, container-closure, manufacturing, and stability patents may provide more practical protection than a basic excipient-composition patent.

FAQs

Can SESQUIENT be reformulated with phosphate or citrate buffer?

Yes, technically, but the change would require a full formulation and regulatory assessment. The alternative buffer would need to match or improve pH control, stability, dilution behavior, particulate performance, and administration tolerability.

Is tromethamine the main patent opportunity in SESQUIENT?

Not by itself. Tromethamine may support formulation claims, but a commercially stronger patent would generally require a defined composition linked to an unexpected stability, compatibility, or administration result.

Could SESQUIENT be sold in a prefilled syringe?

Potentially. A prefilled syringe would require demonstrated stability in the syringe system, validated sterility, acceptable extractables and leachables, reliable dose delivery, and packaging appropriate for emergency-use settings.

Does SESQUIENT have biosimilar risk?

No. Fosphenytoin sodium is a small-molecule drug. Competition would arise through generic or 505(b)(2)-type pathways rather than the biosimilar pathway.

What is the most defensible commercial differentiation for SESQUIENT?

The most defensible differentiation is likely a combination of ready-to-administer packaging, validated stability, device integration, hospital workflow benefits, and reliable supply. A modest excipient substitution alone is less likely to create durable market protection.

References

1. U.S. Food and Drug Administration. (2022). Sesquient (fosphenytoin sodium) injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant DNA origin. FDA.